InflaRx N.V. (IFRX)
2.22
-0.01 (0.45%)
Upcoming Events
Latest Headlines
InflaRx Announces Participation in September Investor Conferences
August 20, 2026 7:30 AM - Globe NewsWire
Form SCHEDULE 13G InflaRx N.V. Filed by: Commodore Capital LP
August 17, 2026 4:34 PM - SEC Filing
Form SCHEDULE 13G/A InflaRx N.V. Filed by: MONTANOVA CAPITAL, LLC
August 14, 2026 4:31 PM - SEC Filing
Form 424B5 InflaRx N.V.
August 14, 2026 4:22 PM - SEC Filing
Form SCHEDULE 13G InflaRx N.V. Filed by: Sirenia Capital Management LP
August 14, 2026 8:35 AM - SEC Filing
Form SCHEDULE 13G/A InflaRx N.V. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 14, 2026 8:22 AM - SEC Filing
Form EFFECT InflaRx N.V.
August 13, 2026 6:06 AM - SEC Filing
Inflarx NV (IFRX) PT Raised to $6 at Cantor Fitzgerald
August 7, 2026 11:09 AM - StreetInsider
Form SCHEDULE 13G InflaRx N.V. Filed by: FMR LLC
August 6, 2026 10:29 AM - SEC Filing
Form F-3 InflaRx N.V.
August 6, 2026 9:21 AM - SEC Filing
Form S-8 InflaRx N.V.
August 6, 2026 9:19 AM - SEC Filing
Form 6-K InflaRx N.V. For: Aug 06
August 6, 2026 7:56 AM - SEC Filing
InflaRx N.V. (IFRX) Misses Q2 EPS by 2c
August 6, 2026 7:33 AM - StreetInsider
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
August 6, 2026 7:30 AM - Globe NewsWire
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
July 30, 2026 7:30 AM - StreetInsider
Form 6-K InflaRx N.V. For: Jun 30
June 30, 2026 4:05 PM - SEC Filing
InflaRx reviews AAV strategy after EMA moves to revoke Tavneos
June 30, 2026 7:31 AM - StreetInsider
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
June 30, 2026 7:30 AM - Globe NewsWire
Full Article List